Cytokines in peritoneal fluid of ovarian neoplasms

Lima, Cid Almeida de; Rodrigues, Isac Souza Silva; Martins-Filho, Agrimaldo; Micheli, Douglas Côbo; Tavares‐Murta, Beatriz Martins; Murta, Eddie Fernando Cândido; Nomelini, Rosekeila Simões

doi:10.1080/01443615.2019.1633516

Cited by 10 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All selected articles passed the STROBE checklist criteria (Supplementary Table S2). These include the articles of Sanna et al [35], Micheli et al [36], de Lima et al [37], Rodrigues et al [38], Kampan et al [25], Wertel et al [39], Zhang et al [40], Crispim et al [41], Shi et al [42], Li et al [43], Dalal et al [44], Han et al [45], Kumar et al [46], Martins-Filho et al [47], Cantón-Romeo et al [48], Sanguinette et al [49], Hao et al [50], Mikuła-Pietrasik et al [51], Chudecka-Głaz et al [ S1 and S2).…”

Section: Strobe Checklistmentioning

confidence: 99%

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Amer¹,

Kartikasari²,

Plebanski³

2021

JPM

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the most lethal cancers, largely due to a late diagnosis. This study aimed to provide a comprehensive meta-analysis on the diagnostic performance of IL6 in the blood and ascites separately for advanced and early-stage OC. We included 37 studies with 6948 participants detecting serum or plasma IL6. The plasma/serum IL6 mean level in the late-stage OC was 23.88 pg/mL (95% CI: 13.84–41.23), and the early-stage OC was 16.67 pg/mL (95% CI: 510.06–27.61), significantly higher than the healthy controls at 3.96 pg/mL (95% CI: 2.02–7.73), but not significantly higher than those found in the controls with benign growths in the ovary, which was 9.63 pg/mL (95% CI: 4.16–22.26). To evaluate IL6 in ascites as a diagnostic marker, we included 26 studies with 1590 participants. The mean level of ascitic IL6 in the late-stage OC was 3676.93 pg/mL (95% CI: 1891.7–7146.7), and the early-stage OC was 1519.21 pg/mL (95% CI: 604.6–3817.7), significantly higher than the benign controls at 247.33 pg/mL (95% CI: 96.2–636.0). There was no significant correlation between the levels of circulating and ascitic IL6. When pooling all OC stages for analysis, we found that serum/plasma IL6 provided 76.7% sensitivity (95% CI: 0.71–0.92) and 72% specificity (95% CI: 0.64–0.79). Ascitic IL6 provided higher sensitivity at 84% (95% CI: 0.710–0.919) and specificity at 74% (95% CI: 0.646–0.826). This study highlights the utility of ascitic IL6 for early detection of OC.

show abstract

Section: Strobe Checklistmentioning

confidence: 99%

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Amer¹,

Kartikasari²,

Plebanski³

2021

JPM

View full text Add to dashboard Cite

show abstract

“…As in our study, another research team detected higher IL-6 levels in ascites from high-grade serous (HGCS) OC patients compared with serum [ 8 ]. In their study, Lima et al [ 28 ] found higher IL-6 values in OC patients compared to those with nonmalignant tumors. Similarly, Dalal et al [ 29 ] showed higher levels of IL-6 in ascites of OC patients compared with controls.…”

Section: Discussionmentioning

confidence: 94%

Prognostic and Clinical Value of Interleukin 6 and CD45⁺CD14⁺ Inflammatory Cells with PD-L1⁺/PD-L2⁺ Expression in Patients with Different Manifestation of Ovarian Cancer

Wertel

Suszczyk

Pawłowska

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiation between malignant and benign tumors, monitoring the progression of the disease, and identification of patients that will respond to implemented treatment. Our study is aimed at evaluating the profile of IL-6 in the plasma and peritoneal fluid (PF) of patients with various clinical manifestations of OC (n=78). We also examined the relationship between IL-6 and PD-L1/PD-L2 positive CD45+CD14+ inflammatory cell (MO/MA) levels in three OC environments (TME): peripheral blood (PB), PF, and tumor (TT) and their clinical and prognostic relevance in OC patients. The expression of PD-L1/PD-L2 molecules was analyzed by flow cytometry. The IL-6 levels were determined by ELISA. We found an elevated level of PD-L1/PD-L2 positive MO/MA in TT compared to PB (p<0.0001). Significantly higher (p<0.0001) levels of IL-6 were observed in PF of the OC patients than in the benign ovarian tumor group (n=31). Additionally, we found higher IL-6 levels in PF than in the plasma of the OC patients. Interestingly, accumulation of IL-6 was observed in PF of patients with low-differentiated OC and correlated with worse prognosis. Moreover, we observed correlations between the level of IL-6 and CD45+CD14+ cells and between CD45+CD14+PD-L1+ cells and the IL-6 level in PF. For the first time, we discovered that the higher percentage of CD45+CD14+PD-L2+ cells in PF predicts better survival of OC patients. Our study suggests that CD45+CD14+PD-L2+ cells and IL-6 may be predictive biomarkers for OC patients. Understanding how the composition of TME changes during OC development and progression is a prerequisite for projecting new therapeutic strategies. Overall, further validation research is warranted.

show abstract

“…The immune system acts directly on tumor tissue with the expression of cytokines and their release into the serum, peritoneal fluid, and intracystic fluid of patients with cancer. This process makes evident the roles of defense cells in the tumor microenvironment, namely the promotion or inhibition of neoplastic cell growth 6 , 8 – 10 , 12 , 13 .…”

Section: Discussionmentioning

confidence: 99%

“…Epithelial ovarian cancer (EOC) develops an inflammatory environment with the presence of immune cells that can promote its growth via the release of cellular signalers and cytokines. However, no consensus on this understanding of the disease has been reached 4 – 6 . The immune cells present in EOC comprise mainly tumor-infiltrating lymphocytes (TILs): T CD4+, T CD8+, natural killer (NK) cells (CD56), and CD3+ and CD20+ T lymphocytes 7 , 8 .…”

Section: Introductionmentioning

confidence: 99%

“…Several theories have been proposed to describe the influence of the immune system on tumor cells and their signaling molecules. Interleukin (IL) levels in ovarian tissue and serum from patients with ovarian cancer have recently been linked to prognostic factors 6 , 9 , 10 . The immune system plays a multifaceted role, promoting and inhibiting tumor growth in different contexts.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunostaining of stromal CD56 cells in ovarian malignancies

Lima

Jammal

Etchebehere

et al. 2023

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY OBJECTIVES: The aim of this study was to evaluate CD56 immunostaining in the stroma of benign and malignant ovarian epithelial neoplasms and associate the CD56 immunostaining with prognostic factors and survival in ovarian cancer. METHODS: Patients with ovarian epithelial neoplasia (n=77) were studied with a prospective cohort. The CD56 immunostaining was evaluated in the peritumoral stroma. Two groups were evaluated: benign ovarian neoplasms (n=40) and malignant ovarian neoplasms (n=37). Data were recorded for histological type and grade, International Federation of Gynecology and Obstetrics staging, molecular subtype, and lymph node metastases. Fisher’s exact test and Kaplan-Meier survival curves were used, with a significance level of ≤0.05. RESULTS: We found greater CD56 stromal immunostaining in malignant neoplasms when compared to the group of benign neoplasms (p=0.00001). There was no significant difference in relation to the prognostic factors and survival. CONCLUSION: Malignant ovarian neoplasms showed higher stromal CD56 immunostaining. As the prognostic value of natural killer in ovarian cancer is controversial, knowing the specific function of each cell present both in the tumor tissue and systemically may help guide successful immunotherapies in the near future.

show abstract

Cytokines in peritoneal fluid of ovarian neoplasms

Cited by 10 publications

References 18 publications

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Prognostic and Clinical Value of Interleukin 6 and CD45⁺CD14⁺ Inflammatory Cells with PD-L1⁺/PD-L2⁺ Expression in Patients with Different Manifestation of Ovarian Cancer

Immunostaining of stromal CD56 cells in ovarian malignancies

Contact Info

Product

Resources

About

Cytokines in peritoneal fluid of ovarian neoplasms

Cited by 10 publications

References 18 publications

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis

Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer

Immunostaining of stromal CD56 cells in ovarian malignancies

Contact Info

Product

Resources

About

Prognostic and Clinical Value of Interleukin 6 and CD45⁺CD14⁺ Inflammatory Cells with PD-L1⁺/PD-L2⁺ Expression in Patients with Different Manifestation of Ovarian Cancer